<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755053</url>
  </required_header>
  <id_info>
    <org_study_id>13071</org_study_id>
    <secondary_id>2008-000718-63</secondary_id>
    <nct_id>NCT00755053</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy of Ovule vs Tablet</brief_title>
  <official_title>An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is focused to prove that the efficacy of a new Canesten formulation (ovule) is not
      inferior to the old Canesten formulation (tablet)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Overall Response at Visit 2 (Day 10 to 14)</measure>
    <time_frame>10-14 days after treatment (=visit 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Overall Response at Visit 3 (Week 6 to 8)</measure>
    <time_frame>6-8 weeks after treatment (=visit 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Clinical Cure at Visit 2 (Day 10 to 14)</measure>
    <time_frame>10-14 days after treatment (=visit 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Clinical Cure at Visit 3 (Week 6 to 8)</measure>
    <time_frame>6-8 weeks after treatment (=visit 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Mycological Cure at Visit 2 (Day 10 to 14)</measure>
    <time_frame>10-14 days after treatment (=visit 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Mycological Cure at Visit 3 (Week 6 to 8)</measure>
    <time_frame>6-8 weeks after treatment (=visit 3)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">466</enrollment>
  <condition>Clotrimazole</condition>
  <condition>Ovulen</condition>
  <condition>Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Clotrimazole tablet (Canesten, BAY-B5097)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clotrimazole ovule (Canesten, BAY-B5097)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole, vaginal ovule</intervention_name>
    <description>Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).</description>
    <arm_group_label>Clotrimazole ovule (Canesten, BAY-B5097)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole, vaginal tablet</intervention_name>
    <description>Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).</description>
    <arm_group_label>Clotrimazole tablet (Canesten, BAY-B5097)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant females aged at least 14 years in Germany or at least 16 years in Russia
             and not older than 50 years.

          -  Subjects presenting a symptomatic vulvovaginal yeast infection confirmed by
             microscopic evaluation (wet mount preparation).

          -  Subjects must be cooperative, able to understand the requirements of the trial
             participation, and willing to participate in the trial. For adolescents the informed
             consent has to be provided to a legal representative in addition.

          -  Subjects of childbearing potential must use an acceptable method of contraception.
             Hormonal or oral contraceptive drugs, intra-uterine devices (IUD) and abstinence are
             considered acceptable methods of contraception.

          -  Negative saline smear for Trichomonas vaginalis

        Exclusion Criteria:

          -  Subjects with known hypersensitivity to imidazoles or triazoles and their analogues.

          -  Subjects presenting a protozoan infection as confirmed by microscopic investigation.

          -  Pregnant, breast feeding or lactating subjects.

          -  Subjects with suspected bacterial vaginal infection.

          -  Subjects with abdominal pain, fever, or foul smelling vaginal discharge.

          -  Subjects who had a vaginal infection, or who had used an intravaginal or systemic
             antimycotic treatment within 60 days prior to visit 1.

          -  Subjects using or wishing to use intra-vaginal or systemic anti-infectives or systemic
             antifungal therapy during the trial.

          -  Subjects wishing to use contraceptive foams, creams, jellies, sponges, therapeutic
             ointments, condoms, diaphragms, and OTC vaginal products during treatment and 3 days
             thereafter (i.e. until day 4).

          -  Subjects unable to refrain from the use of vaginal tampons during treatment and for 3
             days thereafter (i.e. until day 4).

          -  Subjects unable to refrain from the use of feminine hygiene products (e.g. douches,
             feminine deodorant products) for 2 weeks (i.e. from visit 1 until visit 2).

          -  Subjects suffering from chronic/recurrent vulvovaginal mycosis, defined as 4 or more
             mycologically proven symptomatic episodes during the last 12 months.

          -  Subjects suffering from diseases (e.g. diabetes, decreased cellular immunity) or being
             treated with drugs (e.g. immunosuppressants, corticosteroids, anti-infectives) which
             may predispose them to mycological infections.

          -  Subjects who received another investigational drug within 30 days before visit 1.

          -  Unwillingness to refrain from sexual activity during 3 days thereafter.

          -  Actual menstruation at visit 1 or expected menstruation within 4 days after visit 1.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-W端rttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>M端nchen</city>
        <state>Bayern</state>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>M端nchen</city>
        <state>Bayern</state>
        <zip>85356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30459</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osnabr端ck</city>
        <state>Niedersachsen</state>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44319</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krefeld</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47799</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>22159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>22359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>119002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2015</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Bayer Consumer Care Inc.</organization>
  </responsible_party>
  <keyword>Clotrimazole</keyword>
  <keyword>Ovule</keyword>
  <keyword>Tablet</keyword>
  <keyword>Vulvovaginal candidiasis</keyword>
  <keyword>Non-inferiority</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

